Real-world data (RWD) have been increasingly used for regulatory decision-making and as a control group for new drug approval applications. RWD is also helpful in understanding information such as risk factors (e.g., pre-existing medical conditions, personal protective equipment, travel, contacts, smoking, and exposure to animals) and vaccination status for the coronavirus disease 2019 (COVID-19). The methodology of utilizing RWD is inconsistent across healthcare institutions. However, there are possible solutions to standardize RWD for clinical data use, which include the use of Clinical Data Interchange Standards Consortium (CDISC) standards, tools, and concepts. This study examines the availability of CDISC and other international standards for the utilization of RWD with concrete examples and presents the potential platform for implementation. We consider the solution currently available to temporarily convert clinical data-warehouse (DWH) data into the Fast Healthcare Interoperability Resources (FHIR) format to comply with the CDISC standard. This approach would allow for converting institution-level standards to national standards as an interim solution until FHIR is supported, mapping national standards to international standards. We believe that the ideal research environment is a data platform that complies with national and international regulations related to RWD applications. Within such a platform, users can share data freely, rather than rely on a specific facility or vendor. Data platform developments are progressing in Japan and globally. In Japan, initiatives to use research data on research data platforms are being conducted. We are experimenting with implementing tools and knowledge shared by CDISC.